Federica Guffanti

930 total citations
33 papers, 577 citations indexed

About

Federica Guffanti is a scholar working on Molecular Biology, Oncology and Reproductive Medicine. According to data from OpenAlex, Federica Guffanti has authored 33 papers receiving a total of 577 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 19 papers in Oncology and 11 papers in Reproductive Medicine. Recurrent topics in Federica Guffanti's work include DNA Repair Mechanisms (11 papers), Ovarian cancer diagnosis and treatment (11 papers) and PARP inhibition in cancer therapy (8 papers). Federica Guffanti is often cited by papers focused on DNA Repair Mechanisms (11 papers), Ovarian cancer diagnosis and treatment (11 papers) and PARP inhibition in cancer therapy (8 papers). Federica Guffanti collaborates with scholars based in Italy, United Kingdom and Switzerland. Federica Guffanti's co-authors include Giovanna Damia, Michela Chiappa, Francesca Ricci, Rosaria Chilà, Francesco Bertoni, Massimo Broggini, Robert Fruscio, Ilaria Colombo, Raffaella Giavazzi and Maria Rosa Bani and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Scientific Reports.

In The Last Decade

Federica Guffanti

30 papers receiving 575 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Federica Guffanti Italy 13 374 300 143 115 84 33 577
Timothy A. Yap United Kingdom 8 289 0.8× 200 0.7× 111 0.8× 146 1.3× 71 0.8× 10 568
Takafumi Kuroda Japan 14 439 1.2× 245 0.8× 172 1.2× 127 1.1× 79 0.9× 26 694
Jeffrey P. Bruce Canada 9 240 0.6× 264 0.9× 154 1.1× 65 0.6× 73 0.9× 26 517
Sergey Karakashev United States 10 636 1.7× 270 0.9× 203 1.4× 55 0.5× 37 0.4× 16 778
Blake W. Goodman United States 3 328 0.9× 385 1.3× 228 1.6× 68 0.6× 52 0.6× 3 588
Shane W. O’Brien United States 12 401 1.1× 188 0.6× 88 0.6× 69 0.6× 34 0.4× 14 602
Azat Garipov United States 6 679 1.8× 182 0.6× 204 1.4× 83 0.7× 46 0.5× 6 837
Huaizeng Chen China 16 514 1.4× 280 0.9× 165 1.2× 124 1.1× 40 0.5× 44 788
Dilu Feng China 14 370 1.0× 180 0.6× 219 1.5× 113 1.0× 80 1.0× 26 649
Lorena Alonso‐Alconada Spain 12 247 0.7× 223 0.7× 216 1.5× 37 0.3× 60 0.7× 20 478

Countries citing papers authored by Federica Guffanti

Since Specialization
Citations

This map shows the geographic impact of Federica Guffanti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federica Guffanti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federica Guffanti more than expected).

Fields of papers citing papers by Federica Guffanti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Federica Guffanti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federica Guffanti. The network helps show where Federica Guffanti may publish in the future.

Co-authorship network of co-authors of Federica Guffanti

This figure shows the co-authorship network connecting the top 25 collaborators of Federica Guffanti. A scholar is included among the top collaborators of Federica Guffanti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Federica Guffanti. Federica Guffanti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Guffanti, Federica, Francesca Ricci, Robert Fruscio, et al.. (2025). Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas. International Journal of Molecular Sciences. 26(12). 5708–5708.
2.
Guffanti, Federica, Giulia Vargiu, Edoardo Micotti, et al.. (2024). Detection of aberrant locomotor activity in a mouse model of lung cancer via home cage monitoring. Frontiers in Oncology. 14. 1504938–1504938.
3.
Guffanti, Federica, Martina Bruna Violatto, África G. Barrientos, et al.. (2024). Tuning of Ultrasmall Gold Nanoparticles Surface Properties Affect Their Biological Fate. Particle & Particle Systems Characterization. 41(11). 2 indexed citations
4.
Chiappa, Michela, Federica Guffanti, Chiara Grasselli, et al.. (2024). Different Patterns of Platinum Resistance in Ovarian Cancer Cells with Homologous Recombination Proficient and Deficient Background. International Journal of Molecular Sciences. 25(5). 3049–3049. 2 indexed citations
5.
Guffanti, Federica, M.F. Alvisi, Raffaella Giavazzi, et al.. (2024). BRCA1 foci test as a predictive biomarker of olaparib response in ovarian cancer patient-derived xenograft models. Frontiers in Pharmacology. 15. 1390116–1390116. 1 indexed citations
6.
Guffanti, Federica, et al.. (2024). Current HRD assays in ovarian cancer: differences, pitfalls, limitations, and novel approaches. Frontiers in Oncology. 14. 1405361–1405361. 8 indexed citations
7.
Ganzinelli, Monica, Federica Guffanti, Navid Sobhani, et al.. (2023). Epithelioid Mesothelioma Patients with Very Long Survival Display Defects in DNA Repair. Cancers. 15(17). 4309–4309. 2 indexed citations
8.
Chiappa, Michela, Federica Guffanti, Monica Lupi, et al.. (2022). Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells. Cancers. 14(7). 1807–1807. 14 indexed citations
9.
Chiappa, Michela, et al.. (2022). Present and Future Perspective on PLK1 Inhibition in Cancer Treatment. Frontiers in Oncology. 12. 903016–903016. 66 indexed citations
10.
Guffanti, Federica, M.F. Alvisi, Alessia Anastasia, et al.. (2021). Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts. British Journal of Cancer. 126(1). 120–128. 25 indexed citations
11.
Fratelli, Maddalena, Giovanna Damia, Federica Guffanti, et al.. (2021). Predictive modeling of gene expression regulation. BMC Bioinformatics. 22(1). 571–571. 2 indexed citations
12.
Chiappa, Michela, Federica Guffanti, Francesco Bertoni, Ilaria Colombo, & Giovanna Damia. (2021). Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. Drug Resistance Updates. 55. 100744–100744. 77 indexed citations
13.
Guffanti, Federica, M.F. Alvisi, Elisa Caiola, et al.. (2020). Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts. Cancers. 12(9). 2398–2398. 9 indexed citations
14.
Barilani, Mario, Alessandro Cherubini, Valentina Bollati, et al.. (2020). A circular RNA map for human induced pluripotent stem cells of foetal origin. EBioMedicine. 57. 102848–102848. 11 indexed citations
15.
Ricci, Francesca, Federica Guffanti, Roberta Affatato, et al.. (2020). Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer.. PubMed. 10(2). 572–580. 11 indexed citations
16.
Gulluni, Federico, Federica Guffanti, Ioanna Mavrommati, et al.. (2019). Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth. Journal of Experimental & Clinical Cancer Research. 38(1). 472–472. 16 indexed citations
17.
Caiola, Elisa, Federica Guffanti, Edoardo Micotti, et al.. (2019). LKB1 Deficiency Renders NSCLC Cells Sensitive to ERK Inhibitors. Journal of Thoracic Oncology. 15(3). 360–370. 27 indexed citations
18.
Rulli, Eliana, Federica Guffanti, Elisa Caiola, et al.. (2016). The 5′UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs. Scientific Reports. 6(1). 39217–39217. 5 indexed citations
19.
Ricci, Francesca, Francesca Bizzaro, Marta Cesca, et al.. (2014). Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations. Cancer Research. 74(23). 6980–6990. 104 indexed citations
20.
Chilà, Rosaria, Monica Lupi, Federica Guffanti, et al.. (2014). Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. Oncotarget. 6(5). 3394–3408. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Timothy A. Yap Breakdown of academic impact, for papers by Takafumi Kuroda Breakdown of academic impact, for papers by Jeffrey P. Bruce Breakdown of academic impact, for papers by Sergey Karakashev Breakdown of academic impact, for papers by Blake W. Goodman Breakdown of academic impact, for papers by Shane W. O’Brien Breakdown of academic impact, for papers by Azat Garipov Breakdown of academic impact, for papers by Huaizeng Chen Breakdown of academic impact, for papers by Dilu Feng Breakdown of academic impact, for papers by Lorena Alonso‐Alconada
Rankless by CCL
2026